From: Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey
Gender | |
 Male | 138 (86%) |
 Female | 23 (14%) |
Age | 12.7 ± 9.1 years (1–74 years) |
Age Distribution | |
 1–5 years | 27 (17%) |
 5–10 years | 53 (33%) |
 11–15 years | 32 (20%) |
 16–20 years | 31 (19%) |
 21–25 years | 6 (4%) |
 26–30 years | 4 (2%) |
 31 + years | 7 (4%) |
Person completing the questionnaire | |
 Parent/Guardian | 153 (95%) |
 Grandparent | 2 (1%) |
 Self | 6 (4%) |
Diagnosis | |
 Autism | 84 (52%) |
 ASD | 77 (48%) |
Country of Residence | |
 United States | 153 (95%) |
 Non-US | 8 (5%) |
Race | |
 White/Caucasian | 103 (64%) |
 African American/Black | 6 (4%) |
 Asian Indian | 14 (9%) |
 Asian non-Indian | 17 (11%) |
 Other | 21 (13%) |
Ethnicity | |
 Hispanic | 17 (11%) |
 Non-Hispanic | 141(88%) |
 unspecified | 3 (2%) |
Autism severity | |
 Mild | 39 (24%) |
 Moderate | 76 (47%) |
 Severe | 45 (28%) |
Developmental History of Autism | |
 Early onset | 82 (51%) |
 Normal development, followed by regression or plateau | 79 (49%) |
 Age at regression/plateau | 20 ± 11 months |
Seizures | 10 (6%) |
Intellectual Disability | 31 (19%) |
Asthma | 7 (4%) |
Use of Psychiatric or Seizure Medications | 65 (39%) |
Duration of usage of ANRC-EP | |
 3–5 months | 47 |
 6–8 months | 15 |
 9–12 months | 21 |
 1–2 years | 35 |
 2–3 years | 24 |
 4 + years | 19 |